RNF43 and cancer: Chemical inhibitors or biologics targeting WNT signaling molecules, such as FZD receptors, β‐catenin, and porcupine are under development.[28] Clinical trials for the treatment of cancer patients with porcupine inhibitors are ongoing, and RNF43 mutations are being defined as predictive biomarkers for patient selection.[29] However, porcupine inhibitors exhibit several off‐target side effects.[30] Therefore, a combination of different inhibitors may be an alternative strategy.